This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genetic Technologies Ltd (GENE)

NASDAQ: Services

Company Cash Flow
Jun 2015 Jun 2014 Jun 2013 Jun 2012
Cash Flow From Operating Activities
Net Income (Loss) -6.76M -9.54M -8.68M -5.42M
Operating Gains/Losses -1.34M 182.50K 405.49K -5.28M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 116.85K -737.12K 155.27K 182.69K
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets -491.00 194.27K -178.00K -15.17K
(Decrease) Increase In Payables -316.20K 69.34K 435.89K -214.30K
(Decrease) Increase In Other Current Liabilities 80.94K -221.81K 14.83K 0.00
(Increase) Decrease In Other Working Capital 591.77K -748.99K 50.23K 194.72K
Other Non-Cash Items 254.55K 156.17K 319.28K 2.18M
Net Cash From Continuing Operations -7.43M -10.34M -6.97M -7.86M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -7.43M -10.34M -6.97M -7.86M
Sale of Property, Plant & Equipment 43.81K 0.00 1.11K 32.21K
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -147.72K -45.11K -49.74K -78.15K
Acquisitions 1.61M 0.00 -117.14K 10.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 -172.34K 0.00 549.97K
Cash Provided by Financing Activities
Net Cash From Investing Activities 1.51M 218.78K -165.77K 504.04K
Issuance of Debt 1.65M 5.25M 0.00 1.02M
Cash Used for Financing Activities
Issuance of Capital Stock 17.86M 6.59M 446.78K 11.16M
Repayment of Long-Term Debt 0.00 0.00 -16.47K -1.08M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -1.97M -619.97K -23.94K 0.00
Net Cash From Financing Activities 17.54M 11.23M 406.38K 11.11M
Effect of Exchange Rate Changes 283.11K -55.04K 72.87K 129.54K
Net Change in Cash & Cash Equivalents 11.90M 1.04M -6.66M 3.89M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

GENE Genetic Technologies Ltd

Chart of GENE

Analysts Ratings for GENE

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 0 0 0 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

GENE Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs